Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children with Neuroblastoma

Trial Profile

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children with Neuroblastoma

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KUR 501 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Neuroblastoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms GINAKIT2

Most Recent Events

  • 13 Nov 2024 Arms increased from 1 to 2. New arm ' Experimental: GINAKIT cells + Etanercept' added newly.
  • 13 Nov 2024 Planned number of patients changed from 36 to 54.
  • 27 Jul 2023 Planned End Date changed from 10 Aug 2034 to 10 Aug 2040.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top